167 related articles for article (PubMed ID: 38778825)
1. Cost-Effectiveness Comparison of Carbon-Ion Radiation Therapy and Transarterial Chemoembolization for Hepatocellular Carcinoma.
Okazaki S; Shibuya K; Shiba S; Takura T; Ohno T
Adv Radiat Oncol; 2024 Apr; 9(4):101441. PubMed ID: 38778825
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of carbon-ion radiotherapy versus stereotactic body radiotherapy for non-small-cell lung cancer.
Okazaki S; Shibuya K; Takura T; Miyasaka Y; Kawamura H; Ohno T
Cancer Sci; 2022 Feb; 113(2):674-683. PubMed ID: 34820994
[TBL] [Abstract][Full Text] [Related]
3. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
[TBL] [Abstract][Full Text] [Related]
4. Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study.
Kolligs F; Arnold D; Golfieri R; Pech M; Peynircioglu B; Pfammatter T; Ronot M; Sangro B; Schaefer N; Maleux G; Munneke G; Pereira H; Zeka B; de Jong N; Helmberger T;
JHEP Rep; 2023 Feb; 5(2):100633. PubMed ID: 36593888
[TBL] [Abstract][Full Text] [Related]
5. Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis.
Patel MV; Davies H; Williams AO; Bromilow T; Baker H; Mealing S; Holmes H; Anderson N; Ahmed O
J Med Econ; 2023; 26(1):1061-1071. PubMed ID: 37632520
[TBL] [Abstract][Full Text] [Related]
6. Transarterial chemoembolization combined with iodine 125 seeds versus transarterial chemoembolization combined with radiofrequency ablation in the treatment of early- and intermediate-stage hepatocellular carcinoma.
Chen L; Kan X; Sun T; Ren Y; Cao Y; Yan L; Liang B; Xiong B; Zheng C
BMC Gastroenterol; 2020 Jun; 20(1):205. PubMed ID: 32600349
[TBL] [Abstract][Full Text] [Related]
7. Combined therapy of transarterial chemoembolization and stereotactic body radiation therapy versus transarterial chemoembolization for ≤5cm hepatocellular carcinoma: Propensity score matching analysis.
Jun BG; Kim SG; Kim YD; Cheon GJ; Han KH; Yoo JJ; Kim YS; Jeong SW; Jang JY; Lee SH; Park S; Kim HS
PLoS One; 2018; 13(10):e0206381. PubMed ID: 30379885
[TBL] [Abstract][Full Text] [Related]
8. Drug-Eluting Bead Transarterial Chemoembolization Versus Radiofrequency Ablation as an Initial Treatment of Single Small (≤ 3 cm) Hepatocellular Carcinoma.
Lee S; Jeong YY; Lee BC; Shin SS; Heo SH; Kim HO; Park C; Jeong WG
J Korean Med Sci; 2023 Oct; 38(42):e362. PubMed ID: 37904659
[TBL] [Abstract][Full Text] [Related]
9. Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis.
Lin CW; Chen YS; Lo GH; Hsu YC; Hsu CC; Wu TC; Yeh JH; Hsiao P; Hsieh PM; Lin HY; Shu CW; Hung CM
BMC Gastroenterol; 2020 Apr; 20(1):99. PubMed ID: 32272898
[TBL] [Abstract][Full Text] [Related]
10. Repeated Carbon-Ion Radiation Therapy for Intrahepatic Recurrent Hepatocellular Carcinoma.
Tomizawa K; Shibuya K; Shiba S; Okazaki S; Miyasaka Y; Oishi M; Okamoto M; Ohno T
Int J Radiat Oncol Biol Phys; 2023 Aug; 116(5):1100-1109. PubMed ID: 36870514
[TBL] [Abstract][Full Text] [Related]
11. Comparison of initial tumor responses to transarterial bland embolization and drug-eluting beads-transarterial chemoembolization in the management of hepatocellular carcinoma: a propensity-score matching analysis.
Guo J; Wang W; Zhang Y; Xu L; Kong J
J Gastrointest Oncol; 2021 Aug; 12(4):1838-1850. PubMed ID: 34532132
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Combined Radiofrequency Ablation with Transarterial Chemoembolization in Patients with Barcelona Clinic Liver Cancer Stage A Hepatocellular Carcinoma Ineligible for Curative Treatment.
Kim AR; Park E; Kwon SY; Park SJ; Kim YJ; Yoo BC; Choe WH; Kim JH; Hwang JH; Park SW; Kim YJ; Park HS; Yu MH; Jeon HJ
Korean J Gastroenterol; 2019 Mar; 73(3):167-176. PubMed ID: 31013560
[TBL] [Abstract][Full Text] [Related]
13. Transarterial chemoembolization combined with microwave ablation and apatinib in patients with Barcelona clinic liver cancer Stage C hepatocellular carcinoma: A propensity score matching analysis.
Shuanggang C; Shen L; Qiu Z; Qi H; Cao F; Xie L; Fan W
J Cancer Res Ther; 2020; 16(2):250-257. PubMed ID: 32474509
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of transarterial chemoembolization combined with lenvatinib as the first-line treatment for advanced hepatocellular carcinoma.
He Y; Lin W; Cai Z; Huang Y; You M; Lei M; Chen R
Front Pharmacol; 2023; 14():1219694. PubMed ID: 37745079
[No Abstract] [Full Text] [Related]
15. Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis.
Chen S; Peng Z; Wei M; Liu W; Dai Z; Wang H; Mei J; Cheong M; Zhang H; Kuang M
BMC Cancer; 2018 Apr; 18(1):392. PubMed ID: 29621988
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Outcomes of Transarterial Chemoembolization Combined with Radiofrequency Ablation Versus Transarterial Chemoembolization Alone for Recurrent Hepatocellular Carcinoma After Surgical Resection.
Song Q; Ren W; Fan L; Zhao M; Mao L; Jiang S; Zhao C; Cui Y
Dig Dis Sci; 2020 Apr; 65(4):1266-1275. PubMed ID: 31312995
[TBL] [Abstract][Full Text] [Related]
17. Transarterial chemoembolization as a substitute to radiofrequency ablation for treating Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma.
Ishikawa K; Chiba T; Ooka Y; Suzuki E; Ogasawara S; Maeda T; Yokoyama M; Inoue M; Wakamatsu T; Kusakabe Y; Saito T; Tawada A; Arai M; Kanda T; Maruyama H; Imazeki F; Kato N
Oncotarget; 2018 Apr; 9(30):21560-21568. PubMed ID: 29765560
[TBL] [Abstract][Full Text] [Related]
18. Chemoembolization versus radiofrequency ablation for single small (≤ 3 cm) hepatocellular carcinoma: a propensity score matching analysis.
Kim GH; Kim JH; Shim JH; Kim SY; Kim PH; Ko HK; Gwon DI; Shin JH; Lee SJ; Chu HH; Won HJ; Shin YM; Kim N
Eur Radiol; 2024 Feb; ():. PubMed ID: 38329504
[TBL] [Abstract][Full Text] [Related]
19. Transarterial Chemoembolization (TACE) Combined with Lenvatinib versus TACE Alone in Intermediate-Stage Hepatocellular Carcinoma Patients Beyond Up-To-Seven Criteria: A Retrospective, Propensity Score-Matched Analysis.
Zhou C; Chang B; Xiang Z; Li Z; Wu C; Bai M; Jiang Z; Huang M; Chen J
Acad Radiol; 2024 May; ():. PubMed ID: 38760273
[TBL] [Abstract][Full Text] [Related]
20. Comparison of outcome between liver resection, radiofrequency ablation, and transarterial therapy for multiple small hepatocellular carcinoma within the Milan criteria.
Oh JH; Sinn DH; Choi GS; Kim JM; Joh JW; Kang TW; Hyun D; Kang W; Gwak GY; Paik YH; Lee JH; Koh KC; Paik SW; Choi MS
Ann Surg Treat Res; 2020 Oct; 99(4):238-246. PubMed ID: 33029483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
